In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback